Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms von Canuso, C.M, Bossie, C.A, Turkoz, I, Alphs, L

Volltext

Paliperidone extended-release (ER) in patients with schizoaffective disorder presenting with manic or depressive symptomatology von Dunner, D.L, Bossie, C.A, Turkoz, I, Canuso, C.M

Volltext

P.607 Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: ASPIRE-2 study von Ionescu, D.F., Canuso, C.M., Fu, D.J., Qiu, X., Lane, R., Lim, P., Hough, D., Drevets, W., Manji, H.

Volltext

P.323 Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: aspire-1 study von Fu, D.J., Canuso, C.M., Ionescu, D.F., Li, X., Lane, R., Lim, P., Hough, D., Drevets, W., Manji, H.

Volltext

Esketamine versus psychoactive comparator for rapid reduction of depressive symptoms in adolescents with major depressive disorder at imminent suicide risk von Moreno, C., Kosik-Gonzalez, C., Fu, D.J., Chen, N., Lane, R., Drevets, W.C., DelBello, M.P., Canuso, C.M.

Volltext

P.8.a.053 A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder von Gharabawi, G.M., Canuso, C.M., Pandina, G.J., Bossie, C.A., Kujawa, M., Kosik-Gonzalez, C., Turkoz, I.

Volltext